BACKGROUND/AIMS: The response rates of HCV infection to interferon therapy vary depending on viral and host factors. We hypothesized that key regulators of the IFN signaling pathway are predictive of treatment outcome. METHODS: We measured the expression of signal transducer and activator of transcription 1 (STAT1) and suppressor of cytokine signaling 3 (SOCS3) in pretreatment liver biopsies. Staining quantitation was compared to treatment outcomes. RESULTS: Forty-nine patients with HCV and 25 patients with HCV/HIV infection treated with peginterferon/ribavirin were analyzed. Pretreatment hepatic SOCS3 expression was higher in non-responders than responders. Genotype 1 responders had similar levels of SOCS3 as genotype 2/3 responders. African Americans (AA) had higher hepatic SOCS3 than non-AA. Pretreatment hepatic SOCS3 was the most powerful independent predictor of sustained virologic response (SVR), even more so than genotype by logistic regression analysis. Failure to achieve SVR and AA race were independently associated with high hepatic SOCS3 levels. The hepatic expression of STAT-1 did not differ between responders and non-responders. CONCLUSIONS: Our data indicate that hepatic SOCS3 is a stronger baseline predictor of antiviral response than viral genotype. Poor response to antiviral therapy in AA may be associated with higher hepatic SOCS3 expression.
BACKGROUND/AIMS: The response rates of HCV infection to interferon therapy vary depending on viral and host factors. We hypothesized that key regulators of the IFN signaling pathway are predictive of treatment outcome. METHODS: We measured the expression of signal transducer and activator of transcription 1 (STAT1) and suppressor of cytokine signaling 3 (SOCS3) in pretreatment liver biopsies. Staining quantitation was compared to treatment outcomes. RESULTS: Forty-nine patients with HCV and 25 patients with HCV/HIV infection treated with peginterferon/ribavirin were analyzed. Pretreatment hepatic SOCS3 expression was higher in non-responders than responders. Genotype 1 responders had similar levels of SOCS3 as genotype 2/3 responders. African Americans (AA) had higher hepatic SOCS3 than non-AA. Pretreatment hepatic SOCS3 was the most powerful independent predictor of sustained virologic response (SVR), even more so than genotype by logistic regression analysis. Failure to achieve SVR and AA race were independently associated with high hepatic SOCS3 levels. The hepatic expression of STAT-1 did not differ between responders and non-responders. CONCLUSIONS: Our data indicate that hepatic SOCS3 is a stronger baseline predictor of antiviral response than viral genotype. Poor response to antiviral therapy in AA may be associated with higher hepatic SOCS3 expression.
Authors: Peter A White; Yong Pan; Anthony J Freeman; George Marinos; Rosemary A Ffrench; Andrew R Lloyd; William D Rawlinson Journal: J Clin Microbiol Date: 2002-11 Impact factor: 5.948
Authors: Gary L Davis; John B Wong; John G McHutchison; Michael P Manns; Joann Harvey; Janice Albrecht Journal: Hepatology Date: 2003-09 Impact factor: 17.425
Authors: Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu Journal: N Engl J Med Date: 2002-09-26 Impact factor: 91.245
Authors: Johannes G Bode; Stephan Ludwig; Christina Ehrhardt; Ute Albrecht; Andreas Erhardt; Fred Schaper; Peter C Heinrich; Dieter Häussinger Journal: FASEB J Date: 2003-01-22 Impact factor: 5.191
Authors: S Knapp; L J Yee; A J Frodsham; B J W Hennig; S Hellier; L Zhang; M Wright; M Chiaramonte; M Graves; H C Thomas; A V S Hill; M R Thursz Journal: Genes Immun Date: 2003-09 Impact factor: 2.676
Authors: Raymond T Chung; Janet Andersen; Paul Volberding; Gregory K Robbins; Tun Liu; Kenneth E Sherman; Marion G Peters; Margaret J Koziel; Atul K Bhan; Beverly Alston; Dodi Colquhoun; Tom Nevin; George Harb; Charles van der Horst Journal: N Engl J Med Date: 2004-07-29 Impact factor: 91.245
Authors: Magdalena Sarasin-Filipowicz; Edward J Oakeley; Francois H T Duong; Verena Christen; Luigi Terracciano; Witold Filipowicz; Markus H Heim Journal: Proc Natl Acad Sci U S A Date: 2008-05-08 Impact factor: 11.205
Authors: Gerry C MacQuillan; W Bastiaan de Boer; Michael A Platten; Kieran A McCaul; William D Reed; Gary P Jeffrey; Jane E Allan Journal: J Med Virol Date: 2002-10 Impact factor: 2.327
Authors: S Murashima; R Kumashiro; T Ide; I Miyajima; T Hino; Y Koga; K Ishii; T Ueno; S Sakisaka; M Sata Journal: J Med Virol Date: 2000-10 Impact factor: 2.327
Authors: Marie-Louise C Vachon; Stephanie H Factor; Andrea D Branch; Maria-Isabel Fiel; Maribel Rodriguez-Torres; Norbert Bräu; Richard K Sterling; Jihad Slim; Andrew H Talal; Douglas T Dieterich; Mark S Sulkowski Journal: J Hepatol Date: 2010-08-21 Impact factor: 25.083
Authors: Alicia Ocaña-Mondragón; José Antonio Mata-Marín; Mario Uriarte-López; Carolina Bekker-Méndez; Enrique Alcalá-Martínez; Rosa María Ribas-Aparicio; Luis Antonio Uribe-Noguéz; Dulce María Rodríguez-Galindo; María de La Luz Martínez-Rodríguez Journal: Biomed Rep Date: 2017-11-03
Authors: Jennifer E Layden; Bamidele O Tayo; Scott J Cotler; Nina M Clark; Kristine Baraoidan; Scott L Friedman; Richard S Cooper Journal: Transplantation Date: 2014-05-27 Impact factor: 4.939